New study aims to decode dangerous fungal infections in cancer patients
NCT ID NCT06878144
First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study will collect medical information and samples from 300 cancer patients who have or are at risk for a serious fungal infection called mucormycosis. Researchers hope to learn more about how the infection develops and how to better diagnose and manage it. Participants will be asked to follow study procedures and attend appointments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could improve how doctors diagnose and manage mucormycosis in cancer patients, potentially leading to better outcomes.
- What could go wrong
- This is an observational study that does not test a new treatment. It may not directly lead to new therapies, and results depend on participant cooperation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
MD Anderson Cancer Center
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection. * Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care. Exclusion Criteria: • Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacterial pneumonia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antifungal isavuconazole under study for rare brain infection
- Can a prosthetic device restore quality of life after facial defects?
- Can a new antibiotic outperform standard care for pneumonia?
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- New PET tracer could spot hidden fungal infections
- New score could help doctors spot fungal pneumonia faster